{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:11:10Z","timestamp":1780416670953,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009010","name":"Novartis Pharmaceuticals UK Ltd Camberley","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.msard.2026.107030","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T07:49:22Z","timestamp":1769500162000},"page":"107030","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world evidence of clinical outcomes and adherence to ofatumumab in the UK and the impact of a patients support programme: A retrospective, non-interventional cohort study"],"prefix":"10.1016","volume":"107","author":[{"given":"David","family":"Paling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cottrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Hamlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"O\u2019Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agne","family":"Straukiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pyry","family":"Kivi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6537-712X","authenticated-orcid":false,"given":"Wendy","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Al-Azki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin","family":"Kondori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2026.107030_bib0029","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4103\/picr.PICR_154_18","article-title":"Study designs: part 2 \u2013 Descriptive studies","volume":"10","author":"Aggarwal","year":"2019","journal-title":"Perspect. Clin. Res."},{"key":"10.1016\/j.msard.2026.107030_bib0037","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1212\/WNL.0000000000203074","article-title":"Compliance and persistence with Ofatumumab treatment in patients with relapsing multiple sclerosis in clinical trials for up to 4 years (P8-3.002)","volume":"100","author":"Alvarez","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107030_bib0007","series-title":"Real-world effectiveness, tolerabilty, and safety of ofatumumab at 12-month follow-up [Internet]","author":"Amin","year":"2023"},{"key":"10.1016\/j.msard.2026.107030_bib0014","doi-asserted-by":"crossref","first-page":"5985","DOI":"10.2147\/DDDT.S315174","article-title":"Profile of Ofatumumab in the treatment of multiple sclerosis: design, development and place in therapy","volume":"18","author":"Awada","year":"2024","journal-title":"Drug Des. Dev. Ther."},{"issue":"10","key":"10.1016\/j.msard.2026.107030_bib0030","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/nep.13742","article-title":"Evidence-based medicine\u2014When observational studies are better than randomized controlled trials","volume":"25","author":"Bosdriesz","year":"2020","journal-title":"Nephrology"},{"issue":"7","key":"10.1016\/j.msard.2026.107030_bib0015","first-page":"915","article-title":"Association between multiple sclerosis disease severity and adherence to disease-modifying therapies","volume":"27","author":"Burkhard","year":"2021","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.msard.2026.107030_bib0016","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2147\/CEOR.S130334","article-title":"Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis","volume":"9","author":"Burks","year":"2017","journal-title":"CEOR"},{"issue":"suppl_D","key":"10.1016\/j.msard.2026.107030_bib0031","doi-asserted-by":"crossref","first-page":"D2","DOI":"10.1093\/eurheartj\/suv035","article-title":"Why do we need observational studies of everyday patients in the real-life setting?","volume":"17","author":"Cohen","year":"2015","journal-title":"Eur. Heart J. Suppl."},{"issue":"1","key":"10.1016\/j.msard.2026.107030_bib0017","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1468-1331.2010.03110.x","article-title":"The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis","volume":"18","author":"Devonshire","year":"2011","journal-title":"Eur. J. Neurol."},{"issue":"15","key":"10.1016\/j.msard.2026.107030_bib0012","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s40265-023-01942-0","article-title":"Escalation versus induction\/high-efficacy treatment strategies for relapsing multiple sclerosis: which is best for patients?","volume":"83","author":"Edan","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.msard.2026.107030_bib0002","unstructured":"EMA. European Medicines Agency. 2021 [cited 2022 Dec 6]. Kesimpta. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kesimpta."},{"key":"10.1016\/j.msard.2026.107030_bib0025","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.msard.2016.05.006","article-title":"Adherence and persistence to drug therapies for multiple sclerosis: A population-based study","volume":"8","author":"Evans","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.msard.2026.107030_bib0011","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","article-title":"Early use of high-efficacy disease\u2011modifying therapies makes the difference in people with multiple sclerosis: an expert opinion","volume":"269","author":"Filippi","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.107030_bib0021","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.96.15_supplement.4521","article-title":"Adherence and compliance with subcutaneous administration of Ofatumumab in relapsing multiple sclerosis (4521)","author":"Fox","year":"2021","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.msard.2026.107030_bib0004","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1177\/13524585221078825","article-title":"Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: results from ASCLEPIOS I and II","volume":"28","author":"G\u00e4rtner","year":"2022","journal-title":"Mult. Scler."},{"issue":"12","key":"10.1016\/j.msard.2026.107030_bib0028","doi-asserted-by":"crossref","first-page":"737","DOI":"10.7556\/jaoa.2017.145","article-title":"Measuring adherence and outcomes in the treatment of patients with multiple sclerosis","volume":"117","author":"Hao","year":"2017","journal-title":"J. Osteopath. Med."},{"issue":"6","key":"10.1016\/j.msard.2026.107030_bib0003","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus Teriflunomide in Multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.msard.2026.107030_bib0006","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1177\/13524585221079731","article-title":"Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5\u2009years","volume":"28","author":"Hauser","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107030_bib0022","first-page":"546","volume":"383","author":"Hauser Stephen","year":"2020"},{"key":"10.1016\/j.msard.2026.107030_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105888","article-title":"Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis","author":"Hersh","year":"2024","journal-title":"Mult. Scler. Relat. Disord. [Internet]"},{"key":"10.1016\/j.msard.2026.107030_bib0036","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1212\/WNL.0000000000205162","article-title":"Real-world persistence of Ofatumumab vs self-injectable or oral disease-modifying therapies in patients with multiple sclerosis (P5-6.012)","volume":"102","author":"Hersh","year":"2024","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.msard.2026.107030_bib0020","article-title":"Adherence to disease-modifying therapies for multiple sclerosis","volume":"22","author":"Higuera","year":"2016","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.msard.2026.107030_bib0035","unstructured":"Internal Unpublished report. Novartis KesimptaConnect weekly report. 2024 Aug 10."},{"issue":"8","key":"10.1016\/j.msard.2026.107030_bib0009","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1177\/13524585211055934","article-title":"Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: phase 2 APOLITOS study","volume":"28","author":"Kira","year":"2022","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2026.107030_bib0018","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.3390\/ijerph19042203","article-title":"Adherence to therapy in patients with multiple sclerosis\u2014Review","volume":"19","author":"Ko\u0142tuniuk","year":"2022","journal-title":"Int. J. Env. Res. Public Health"},{"issue":"1","key":"10.1016\/j.msard.2026.107030_bib0026","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40120-024-00674-x","article-title":"TEC-ADHERE: real-world persistence and adherence on dimethyl fumarate in patients with relapsing\u2013Remitting multiple sclerosis in the French OroSEP patient-Support program","volume":"14","author":"Labauge","year":"2025","journal-title":"Neurol. Ther."},{"issue":"9","key":"10.1016\/j.msard.2026.107030_bib0032","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.18553\/jmcp.2021.27.9.1273","article-title":"Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression","volume":"27","author":"Mardan","year":"2021","journal-title":"JMCP"},{"issue":"6","key":"10.1016\/j.msard.2026.107030_bib0013","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.autrev.2017.04.010","article-title":"Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review","volume":"16","author":"Merkel","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2026.107030_bib0023","series-title":"Ofatumumab for treating relapsing multiple sclerosis [Internet]","year":"2022"},{"key":"10.1016\/j.msard.2026.107030_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/PPA.S8230","article-title":"Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence","volume":"4","author":"Patti","year":"2010","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.msard.2026.107030_bib0001","unstructured":"Relapsing Remitting MS (RRMS) - MS Relapse Signs | MS Society [Internet]. [cited 2024 Jul 17]. Available from: https:\/\/www.mssociety.org.uk\/about-ms\/types-of-ms\/relapsing-remitting-ms."},{"issue":"18","key":"10.1016\/j.msard.2026.107030_bib0034","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2217\/cer-2020-0122","article-title":"Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis","volume":"9","author":"Samjoo","year":"2020","journal-title":"J. Comp. Eff. Res."},{"key":"10.1016\/j.msard.2026.107030_bib0005","volume":"66","author":"Samjoo","year":"2022"},{"key":"10.1016\/j.msard.2026.107030_bib0010","series-title":"Real-world change in annualised relapse rate following initiation of ofatumumab in patients with multiple sclerosis [Internet]","author":"Tai","year":"2024"},{"issue":"4","key":"10.1016\/j.msard.2026.107030_bib0019","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00415-021-10850-w","article-title":"Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review","volume":"269","author":"Washington","year":"2022","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.107030_bib0027","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00415-021-10850-w","article-title":"Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review","volume":"269","author":"Washington","year":"2022","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2026.107030_bib0008","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1007\/s00415-024-12360-x","article-title":"Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study","volume":"271","author":"Zangh\u00ec","year":"2024","journal-title":"J. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826000660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826000660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:54:04Z","timestamp":1780415644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826000660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":37,"alternative-id":["S2211034826000660"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107030","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world evidence of clinical outcomes and adherence to ofatumumab in the UK and the impact of a patients support programme: A retrospective, non-interventional cohort study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107030"}}